Novo Nordisk acquires Corvidia for $2.1B with an upfront payment of $725M in cash Sofinnova Partners co-founded Corvidia as its sole seed financial investor in 2015 with serial entrepreneur Michael Davidson PARIS, France – June 11, 2020 - Sofinnova Partners, a leading European life sciences venture capital firm...
• Contract guarantees sales volume for Sarnia plant during its first three years ofoperation • Agreement ensures BioAmberis the principal supplier to a key emerging buyer of succinic acid • PTTMCC selection of BioAmber as supplier validates bio-‐succinic cost competitiveness and quality
Paris, le 15 septembre 2011 : STENTYS (FR0010949404 – STNT), société de technologie médicale qui commercialise le premier et le seul stent auto¬apposant pour le traitement de l’infarctus du myocarde, annonce aujourd’hui que son stent autoapposant a été implanté dans plus de 1 000 patients dans le monde.
First Commercial ICAO-Lite Deployment Provides Secure, Intelligent Credentials for both Access Control and Identity
© 2020 Sofinnova Partners TERMS AND CONDITIONS